Literature DB >> 26190482

The latest idea in NAFLD/NASH pathogenesis.

Masafumi Ono1, Nobuto Okamoto2, Toshiji Saibara2.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a metabolic disorder characterized by fatty accumulation in the liver without alcohol consumption. NAFLD ranges from simple steatosis to nonalcoholic steatohepatitis (NASH), which may progress to end-stage liver disease. The prevalence of NAFLD is rising because of an increasing prevalence of obesity and metabolic syndrome. The progression of these diseases is considered to be related to metabolic syndrome, which is characterized by obesity, glucose impairment, dyslipidemia, hypertension, and adipocytokine impairment. In addition, the pathogenesis of NAFLD/NASH is considered to be multifactorial and complex and is influenced by lifestyle habits, nutritional factors, and genetics. In particular, the PNPLA3 gene has been recently recognized as the most important functional gene polymorphism in the progression of NASH. Disruption in hepatic lipid metabolism is closely related to the development of fatty liver. Accumulation of excess triglycerides (TGs) induces hepatic steatosis. However, TG accumulation itself is not harmful to hepatocytes and may instead act as a protective mechanism against free fatty acid (FFA)-induced lipotoxicity. Excess FFAs also contribute to hepatotoxicity in NAFLD/NASH because oxidation of FFAs in hepatic microsomes generates excessive oxidative stress. Oxidative stress is considered one of the most important pathogenic factors in the development of NASH. Mitochondrial abnormalities, which are frequently observed in NASH-affected livers, are associated with impaired electron transport and result in further oxidative stress formation. The aims of this review are to assess the mechanisms of lipid metabolism and hepatic steatosis, the background of the disease, and the potential molecular mechanisms involved.

Entities:  

Keywords:  Adipocytokine impairment; Lipotoxicity; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Oxidative stress; PNPLA3

Year:  2010        PMID: 26190482     DOI: 10.1007/s12328-010-0182-9

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  92 in total

1.  PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease.

Authors:  Elizabeth K Speliotes; Johannah L Butler; Cameron D Palmer; Benjamin F Voight; Joel N Hirschhorn
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

2.  Expression, regulation, and triglyceride hydrolase activity of Adiponutrin family members.

Authors:  Andrew C Lake; Ying Sun; Jian-Liang Li; Jae Eun Kim; Jeremy W Johnson; Dongmei Li; Tracy Revett; Heather H Shih; Wei Liu; Janet E Paulsen; Ruth E Gimeno
Journal:  J Lipid Res       Date:  2005-09-08       Impact factor: 5.922

3.  Adipose tissues as an ancestral immune organ: site-specific change in obesity.

Authors:  S Caspar-Bauguil; B Cousin; A Galinier; C Segafredo; M Nibbelink; M André; L Casteilla; L Pénicaud
Journal:  FEBS Lett       Date:  2005-07-04       Impact factor: 4.124

4.  Variation in the adiponutrin gene influences its expression and associates with obesity.

Authors:  Lovisa E Johansson; Johan Hoffstedt; Hemang Parikh; Emma Carlsson; Martin Wabitsch; Anne-Greth Bondeson; Jan Hedenbro; Hans Tornqvist; Leif Groop; Martin Ridderstråle
Journal:  Diabetes       Date:  2006-03       Impact factor: 9.461

5.  Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling.

Authors:  Jörn M Schattenberg; Yongjun Wang; Rajat Singh; Raina M Rigoli; Mark J Czaja
Journal:  J Biol Chem       Date:  2005-01-04       Impact factor: 5.157

Review 6.  Mitochondrial injury in steatohepatitis.

Authors:  Dominique Pessayre; Bernard Fromenty; Abdellah Mansouri
Journal:  Eur J Gastroenterol Hepatol       Date:  2004-11       Impact factor: 2.566

7.  Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis.

Authors:  Shiro Yokohama; Masashi Yoneda; Masakazu Haneda; Satoshi Okamoto; Mituyoshi Okada; Kazunobu Aso; Takenao Hasegawa; Yoshihiko Tokusashi; Naoyuki Miyokawa; Kimihide Nakamura
Journal:  Hepatology       Date:  2004-11       Impact factor: 17.425

Review 8.  Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis.

Authors:  Rajasekhara R Mummadi; Krishna S Kasturi; Swapna Chennareddygari; Gagan K Sood
Journal:  Clin Gastroenterol Hepatol       Date:  2008-08-19       Impact factor: 11.382

9.  Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

Authors:  Jason M Hui; Alex Hodge; Geoffrey C Farrell; James G Kench; Adamandia Kriketos; Jacob George
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

10.  Adiponectin and protection against type 2 diabetes mellitus.

Authors:  Joachim Spranger; Anja Kroke; Matthias Möhlig; Manuela M Bergmann; Michael Ristow; Heiner Boeing; Andreas F H Pfeiffer
Journal:  Lancet       Date:  2003-01-18       Impact factor: 79.321

View more
  8 in total

Review 1.  NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook.

Authors:  Alberto Nascè; Karim Gariani; François R Jornayvaz; Ildiko Szanto
Journal:  Antioxidants (Basel)       Date:  2022-06-09

2.  Angiotensin receptor blockade recovers hepatic UCP2 expression and aconitase and SDH activities and ameliorates hepatic oxidative damage in insulin resistant rats.

Authors:  Priscilla Montez; José Pablo Vázquez-Medina; Rubén Rodríguez; Max A Thorwald; José A Viscarra; Lisa Lam; Janos Peti-Peterdi; Daisuke Nakano; Akira Nishiyama; Rudy M Ortiz
Journal:  Endocrinology       Date:  2012-10-18       Impact factor: 4.736

Review 3.  Management of immunosuppressant agents following liver transplantation: Less is more.

Authors:  Mustafa S Ascha; Mona L Ascha; Ibrahim A Hanouneh
Journal:  World J Hepatol       Date:  2016-01-28

4.  Nonalcoholic Fatty Liver Disease in Hispanic Youth With Dysglycemia: Risk for Subclinical Atherosclerosis?

Authors:  Fida Bacha; Anca Tomsa; Sara K Bartz; Sarah E Barlow; Zili David Chu; Ramkumar Krishnamurthy; Rajesh Krishnamurthy; E O'Brian Smith
Journal:  J Endocr Soc       Date:  2017-06-27

Review 5.  Do Coffee Polyphenols Have a Preventive Action on Metabolic Syndrome Associated Endothelial Dysfunctions? An Assessment of the Current Evidence.

Authors:  Kazuo Yamagata
Journal:  Antioxidants (Basel)       Date:  2018-02-04

Review 6.  Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?

Authors:  Agostino Di Ciaula; Salvatore Passarella; Harshitha Shanmugam; Marica Noviello; Leonilde Bonfrate; David Q-H Wang; Piero Portincasa
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

7.  Histopathological characteristics of glutamine synthetase-positive hepatic tumor lesions in a mouse model of spontaneous metabolic syndrome (TSOD mouse).

Authors:  Tetsuyuki Takahashi; Takeshi Nishida; Hayato Baba; Hideki Hatta; Johji Imura; Mitsuko Sutoh; Syunji Toyohara; Ryoji Hokao; Syunsuke Watanabe; Hirohisa Ogawa; Hisanori Uehara; Koichi Tsuneyama
Journal:  Mol Clin Oncol       Date:  2016-06-09

Review 8.  Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests.

Authors:  Agostino Di Ciaula; Giuseppe Calamita; Harshitha Shanmugam; Mohamad Khalil; Leonilde Bonfrate; David Q-H Wang; Gyorgy Baffy; Piero Portincasa
Journal:  Int J Mol Sci       Date:  2021-07-19       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.